Market cap
$33.6m
End-of-day close multiplied by current shares on issue.
Result releasedAnnolyse analysis published
The NZ$25m acquisition price is relevant to debt headroom, while borrowings and gearing remain the direct evidence.
Revenue context before the current result.
EBITDAF margin across covered periods.
Operating cash flow across covered periods.
Statutory profit after tax across covered periods.
Market context
These ratios pair a market close from around the result date with verified filing data. An unavailable metric means the required inputs were missing or unsuitable for comparison.
The latest close and share count context for the market price.
Market cap
$33.6m
End-of-day close multiplied by current shares on issue.
How the market price compares with recent earnings and cash-flow inputs.
P/E
Not available
Not available for this company right now.
EPS
Not available
Not available for this company right now.
PEG
Not available
Not available for this company right now.
EV/EBITDA
Not available
Not available for this company right now.
P/FCF
Not available
Not available for this company right now.
P/B
0.59x
Market value compared with latest reported equity.
Yield and investment-company valuation where supported.
Dividend yield
0.0%
Trailing dividends compared with the latest close.
Total return
Not available
Available once dividend and adjustment data are verified.
Key metrics
HY27 vs HY26
Revenue
$21.8m
Caveat: metric quality flags apply; use this value with basis context.
Net profit after tax
$1.3m
Caveat: metric quality flags apply; use this value with basis context.
Net cash inflow from operating activities
$2.3m
Caveat: metric quality flags apply; use this value with basis context.
Interim dividend per share
0.72c
— vs —
Profit before tax
$2m
Caveat: metric quality flags apply; use this value with basis context.
Cash and cash equivalents
$0.11m
-12.6% ↓ vs $0.13m
Total assets
$202.8m
Caveat: metric quality flags apply; use this value with basis context.
Analysis ofPHL HY27Result releasedAnnolyse analysis published
What changed
Current cash conversion was 61.0% of underlying EBITDAF; a comparable prior-period ratio is unavailable, so a conversion trend cannot be established.
Revenue increased 13.7% to NZD 21.8 million. Underlying EBITDAF was NZD 3.8 million, with management citing NZD 2.55 million for HY26. Statutory profit before tax rose to NZD 2.0 million from NZD 0.2 million, while NPAT moved from a NZD 49,000 loss to a NZD 1.3 million profit.
Gross borrowings declined to NZD 41.7 million from NZD 43.5 million, but cash remained just NZD 0.1 million. No segment breakdown is available to establish which facilities or revenue streams contributed most to the improvement.
What matters
Chatswood Retirement Limited acquisition adds balance-sheet context, with NZ$25m acquisition price, but borrowings and gearing are the direct leverage evidence.
Lower operating cash flow means the stronger income statement did not produce a matching increase in cash available to support investment and financing commitments. The supplied disclosures do not identify the cause, so neither collection timing nor working-capital pressure can be asserted.
Operating improvement is more informative than the statutory profit rebound alone. Underlying EBITDAF excludes fair-value adjustments and items considered non-trading in nature or size, making it the issuer’s preferred operating measure. For an aged-care business, sustained occupancy, care funding and staffing costs are essential to judging durability, but the supplied material does not quantify their individual contributions.
Debt reduction improves the balance-sheet position, but liquidity remains important. Calculated net debt, defined as gross borrowings less cash, was NZD 41.6 million versus NZD 43.3 million. The small cash balance means financial flexibility depends on ongoing cash generation and available funding facilities, whose headroom is not supplied.
Expectations
That establishes a numeric commitment, but the supplied material does not provide a sufficiently clear operating bridge to judge delivery confidence. Investors need to distinguish the earnings already demonstrated from the assumptions supporting the full-year target.
FY26 revenue was modestly second-half weighted: HY26 contributed 47.8% of annual revenue. That offers limited context rather than a dependable earnings-seasonality rule. Management cites sustained high occupancy, while the prior release referred to a 95% site occupancy target; current facility-level occupancy and performance against that threshold are not supplied, limiting assessment of remaining operating upside.
Quality of result
The result contains evidence of better operating earnings, but weaker statutory operating cash flow prevents an unqualified quality assessment. Capital expenditure increased to NZD 0.8 million from NZD 0.3 million, contributing to calculated pre-lease free cash flow falling to NZD 1.5 million from NZD 2.5 million. Capex affects this free-cash-flow measure, not operating cash conversion. Separate current trade receivables and a quantified working-capital cash-flow movement are unavailable, leaving the cash-flow explanation unresolved.
Company-defined Operating Free Cash Flow was NZD 1.0 million. Its definition starts with underlying EBITDAF and deducts cash interest, committed debt repayments, cash tax payable and maintenance capex; it is not directly comparable with calculated pre-lease free cash flow. The company’s disclosed dividend payout was 38.2% of its free-cash-flow measure. This supports assessment of the current interim distribution, not an annual dividend policy or proof that statutory cash generation strengthened.
Unresolved
This briefing cannot assess facility-level profitability, funding headroom or the durability of cash generation from the supplied disclosures.
Chat
Ask follow-up questions about Promisia Healthcare's HY27 result.
Informational only. No buy, sell, hold, price-target, or personal financial advice.
Informational only. No buy, sell, hold, price-target, or personal financial advice.
Open to load analytical metrics.
Open to load key metrics.
PHL HY27 Interim Report
HY27 / financial reportPHL HY27 NZX Results Announcement
HY27 / results announcementPHL HY27 Results Announcement
HY27 / results releasePHL HY26 Preliminary Financial Statements
HY26 / financial reportPHL HY26 Results Announcement
HY26 / results releasePHL HY26 NZX Results Announcement
HY26 / results announcementPHL 2026 Annual Report
FY26 / financial reportFY26 Earnings Guidance Upgrade
FY26 / commentaryPresentation - ASM 2025
HY26 / commentaryPresentation - ASM 2026
HY27 / commentaryRelated insights
Compare this result's metrics with other covered NZX companies.
Leverage and balance-sheet risk
Net debt / EBITDA is 10.87x for this result.
Cash conversion quality
This result converted 61.0% of EBITDA to operating cash flow.
Dividend coverage and payout pressure
Company-disclosed payout ratio is 38.2% on an FCF basis, with NPAT payout at 28.9%.
Revenue growth context
Revenue growth was 13.7% for this reporting period.
Get the next Promisia Healthcare briefing and related NZX reporting-season updates by email.